{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-111481","form_type":"8-K","ticker":null,"cik":"0001597553","company_name":"Sage Therapeutics, Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.151280+00:00","generated_at":"2026-06-03T08:00:18.028075+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sage Q1: $6.2M ZURZUVAE revenue, fails Phase 2 Parkinson's study; net loss $108.5M","bullets":["ZURZUVAE collaboration revenue $6.2M (50% of Biogen net); 700+ prescriptions shipped in Q1.","Phase 2 PRECEDENT (dalzanemdor in Parkinson's MCI) missed primary endpoint; no further development planned.","Cash, equivalents, securities $717M at Mar 31, 2024, down from $753M at Dec 31, 2023.","Net loss $108.5M vs $146.8M YoY; R&D expenses $71.7M, SG&A $52.6M, both down YoY.","Payor coverage >65% of commercial lives for ZURZUVAE; guidance: cash into 2026, expenses down in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-111481","json":"https://secwatch.observer/filing/0001193125-24-111481.json","markdown":"https://secwatch.observer/filing/0001193125-24-111481.md","text":"https://secwatch.observer/filing/0001193125-24-111481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1597553/000119312524111481/0001193125-24-111481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1597553/000119312524111481/d800679d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T08:00:18.028075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34e6ef1cd49afc209aee3f3ff8f9a74bce949596","claim":"Sage Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.2 million in ZURZUVAE collaboration revenue.","evidence_excerpt":"filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Achieved $6.2 million in ZURZUVAE TM (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by Biogen Encouraging initial demand for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1597553/000119312524111481/0001193125-24-111481-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$6.2 million in ZURZUVAE collaboration revenue"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}